|
產品描述： Avasimibe (CI-1011; PD-148515) is an orally active acyl coenzyme A-cholesterol acyltransferase (ACAT; also called SOAT)) inhibitor with IC50s of 24 and 9.2 μM for ACAT1 and ACAT2, respectively. Avasimibe can be used for the research of prostate cancer |
|
靶點：
ACAT1:24 μM (IC50)；ACAT2：9.2 μM (IC50);P450;Acyltransferase |
體內研究：
Avasimibe (30 mg/kg, intraperitoneally injected on alternate days for 7 weeks) suppresses PCa cell growth and metastasis in vivo. Avasimibe has good biocompatibility and low toxicity |
參考文獻：
1. Taichi Ohshiro,et al. Pyripyropene A, an acyl-coenzyme A:cholesterol acyltransferase 2-selective inhibitor, attenuates hypercholesterolemia and atherosclerosis in murine models of hyperlipidemia. Arterioscler Thromb Vasc Biol. 2011 May;31(5):1108-15. 2. Kangping Xiong, et al. The cholesterol esterification inhibitor avasimibe suppresses tumour proliferation and metastasis via the E2F-1 signalling pathway in prostate cancer.Cancer Cell Int. 2021 Aug 30;21(1):461. |
|
溶解性：
DMSO : 100 mg/mL (199.31 mM; Need ultrasonic) |
|
保存條件：
-20℃ |
配置溶液濃度參考：
|
1mg |
5mg |
10mg |
| 1 mM |
1.993 ml |
9.966 ml |
19.931 ml |
| 5 mM |
0.399 ml |
1.993 ml |
3.986 ml |
| 10 mM |
0.199 ml |
0.997 ml |
1.993 ml |
| 50 mM |
0.04 ml |
0.199 ml |
0.399 ml |
|
| 注意： |
部分產品我司僅能提供部分信息，我司不保證所提供信息的權威性，僅供客戶參考交流研究之用。 |
上海工商
危險品化學品經營許可證（不帶存儲）
營業執照(三證合一)
北京